Skip to content
Cyclophosphamide for myasthenia gravis: a comeback? episode artwork

Apr 17, 2025 37 min

Cyclophosphamide for myasthenia gravis: a comeback?

from JNNP Podcast Hosted by BMJ Group

Patients with refractory or high-risk myasthenia gravis (MG) respond poorly to conventional immunosuppressive therapy, requiring rescue therapies and often experiencing treatment toxicity. The study discussed in this podcast suggests that lower doses of cyclophosphamide can be effective and safe in people with MG, including older age. JNNP's podcast editor, Saima Chaudhry, is joined by Professor Carolina Barnett-Tapia, University of Toronto, University Health Network, who authors the editorial comment 'Cyclophosphamide for myasthenia gravis: a comeback?'(https://jnnp.bmj.com/content/95/12/1095). The original paper is also free to access: https://jnnp.bmj.com/content/95/12/1096. Please subscribe to the show on Apple Podcasts, Spotify or find it on your platform of choice. Your feedback and reviews are very appreciated. Follow JNNP on twitter: @JNNP_BMJ

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Cyclophosphamide for myasthenia gravis: a comeback?

0:00 37:58

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of JNNP Podcast?

This episode is 37 minutes long.

When was this JNNP Podcast episode published?

This episode was published on April 17, 2025.

Can I download this JNNP Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.